Government pressure could see mass resignations of Hungarian doctors

The Hungarian government has demonised the Hungarian Medical Chamber (MOK) after the doctor's union warned its members not to sign up to an on-call system for GPs. It sparks fresh concerns of a workforce exodus at a time when patients are increasingly turn to private care - and could be a boon for for-profits.

Softened Hungarian reform still risks workforce exodus

The Hungarian government has removed from its proposed new health care law the requirement that private doctors would need to work at least 20 hours a month in the public sector. However, the rest of the controversial reform remains unaltered.

Hungarian reforms risk mass doctor exodus to private pay, and abroad

Around 4,500 Hungarian doctors have threatened to resign en masse, after the government announced controversial reforms which include an option to reduce wages based on vague performance metrics. HBI hears this could drive large numbers into Hungary’s growing private sector.

Affidea deal – underbidders and EBITDA

HBI hears that the surprise buyer of European imaging and cancer treatment provider Affidea, Groupe Bruxelles Lambert (GBL) may not have been the highest bidder, despite winning out. HBI considers who else was in the running, and the EBITDA figure that may have been used for the deal.

Hungary facing four more years of Orbanomics

After the crushing victory of national-conservative Fidesz, led by Viktor Orban, the Hungarian healthcare sector awaits another four years of “Orbanomics”. HBI speaks with a Hungarian contact to learn more.

Affidea bought by Groupe Bruxelles Lambert

Groupe Bruxelles Lambert (“GBL”) has signed definitive agreements to acquire a majority stake in European imaging and cancer treatment provider Affidea from B-FLEXION, the private investment firm of the Switzerland-based billionaire Bertarelli family. GBL will invest up to €1bn of equity for the transaction which is its first substantive healthcare investment.

Will record results for Synlab precipitate Cinven sale?

Almost a year after its IPO, lab giant Synlab has posted strong FY21 results bolstered by Covid, but not, it says, dependant on it. Management say extra cash will be used as a springboard for growth. Could it also lead to private equity majority shareholder Cinven selling its remaining interest?

Find Us